(EMN) Eastman Chemical - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2774321002
Stock: Specialty Materials, Polymers, Films, Fibers, Chemicals
Total Rating 35
Risk 80
Buy Signal -0.82
| Risk 5d forecast | |
|---|---|
| Volatility | 35.3% |
| Relative Tail Risk | -11.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.55 |
| Alpha | -41.82 |
| Character TTM | |
|---|---|
| Beta | 1.035 |
| Beta Downside | 1.303 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.40% |
| CAGR/Max DD | -0.01 |
EPS (Earnings per Share)
Revenue
Description: EMN Eastman Chemical March 04, 2026
Eastman Chemical Company (EMN) is a specialty materials company operating globally. It is classified under the Diversified Chemicals GICS Sub Industry, a sector known for producing a wide range of chemical products.
The company operates through four main segments. The Additives & Functional Products segment supplies materials like amine derivatives and specialty polymers to various markets including transportation and agriculture. The Advanced Materials segment focuses on products such as copolyesters and polyvinyl butyral sheets, serving industries like automotive and electronics. Chemical Intermediates provides olefin and acetyl derivatives, and plasticizers for industrial and construction applications. The Fibers segment produces cellulose acetate for filtration media, primarily cigarette filters, and other uses. This multi-segment approach is typical of diversified chemical companies, allowing them to serve a broad customer base and mitigate risk across different end-markets.
Investors should continue their research on ValueRay for detailed financial metrics and performance analysis.
Headlines to watch out for
Specialty materials demand drives revenue growth | Raw material costs impact profit margins | Global economic slowdown reduces industrial chemical sales | Regulatory changes affect chemical product formulations
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 474.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.67 > 1.0 |
| NWC/Revenue: 11.35% < 20% (prev 14.85%; Δ -3.50% < -1%) |
| CFO/TA 0.07 > 3% & CFO 970.0m > Net Income 474.0m |
| Net Debt (4.51b) to EBITDA (1.30b): 3.48 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.9m) vs 12m ago -2.54% < -2% |
| Gross Margin: 21.07% > 18% (prev 0.24%; Δ 2083 % > 0.5%) |
| Asset Turnover: 58.21% > 50% (prev 61.67%; Δ -3.46% > 0%) |
| Interest Coverage Ratio: 3.62 > 6 (EBITDA TTM 1.30b / Interest Expense TTM 217.0m) |
Altman Z'' 4.19
| A: 0.07 (Total Current Assets 3.65b - Total Current Liabilities 2.65b) / Total Assets 14.86b |
| B: 0.68 (Retained Earnings 10.11b / Total Assets 14.86b) |
| C: 0.05 (EBIT TTM 785.0m / Avg Total Assets 15.04b) |
| D: 1.13 (Book Value of Equity 9.95b / Total Liabilities 8.82b) |
| Altman-Z'' Score: 4.19 = AA |
Beneish M -3.04
| DSRI: 0.91 (Receivables 999.0m/1.17b, Revenue 8.75b/9.38b) |
| GMI: 1.16 (GM 21.07% / 24.41%) |
| AQI: 0.99 (AQ_t 0.36 / AQ_t-1 0.36) |
| SGI: 0.93 (Revenue 8.75b / 9.38b) |
| TATA: -0.03 (NI 474.0m - CFO 970.0m) / TA 14.86b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of EMN shares?
As of March 08, 2026, the stock is trading at USD 70.33 with a total of 1,257,298 shares traded.
Over the past week, the price has changed by -6.86%, over one month by -9.17%, over three months by +17.94% and over the past year by -24.10%.
Over the past week, the price has changed by -6.86%, over one month by -9.17%, over three months by +17.94% and over the past year by -24.10%.
Is EMN a buy, sell or hold?
Eastman Chemical has received a consensus analysts rating of 4.15.
Therefore, it is recommended to buy EMN.
- StrongBuy: 10
- Buy: 3
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 76.6 | 8.9% |
| Analysts Target Price | 76.6 | 8.9% |
EMN Fundamental Data Overview March 05, 2026
P/E Trailing = 18.0878
P/E Forward = 12.5628
P/S = 0.9666
P/B = 1.4403
P/EG = 3.5907
Revenue TTM = 8.75b USD
EBIT TTM = 785.0m USD
EBITDA TTM = 1.30b USD
Long Term Debt = 4.20b USD (from longTermDebt, last quarter)
Short Term Debt = 642.0m USD (from shortTermDebt, last quarter)
Debt = 5.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.51b USD (from netDebt column, last quarter)
Enterprise Value = 12.97b USD (8.46b + Debt 5.08b - CCE 566.0m)
Interest Coverage Ratio = 3.62 (Ebit TTM 785.0m / Interest Expense TTM 217.0m)
EV/FCF = 30.59x (Enterprise Value 12.97b / FCF TTM 424.0m)
FCF Yield = 3.27% (FCF TTM 424.0m / Enterprise Value 12.97b)
FCF Margin = 4.84% (FCF TTM 424.0m / Revenue TTM 8.75b)
Net Margin = 5.42% (Net Income TTM 474.0m / Revenue TTM 8.75b)
Gross Margin = 21.07% ((Revenue TTM 8.75b - Cost of Revenue TTM 6.91b) / Revenue TTM)
Gross Margin QoQ = 17.13% (prev 19.66%)
Tobins Q-Ratio = 0.87 (Enterprise Value 12.97b / Total Assets 14.86b)
Interest Expense / Debt = 1.02% (Interest Expense 52.0m / Debt 5.08b)
Taxrate = 16.37% (93.0m / 568.0m)
NOPAT = 656.5m (EBIT 785.0m * (1 - 16.37%))
Current Ratio = 1.37 (Total Current Assets 3.65b / Total Current Liabilities 2.65b)
Debt / Equity = 0.85 (Debt 5.08b / totalStockholderEquity, last quarter 5.96b)
Debt / EBITDA = 3.48 (Net Debt 4.51b / EBITDA 1.30b)
Debt / FCF = 10.64 (Net Debt 4.51b / FCF TTM 424.0m)
Total Stockholder Equity = 5.86b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.15% (Net Income 474.0m / Total Assets 14.86b)
RoE = 8.09% (Net Income TTM 474.0m / Total Stockholder Equity 5.86b)
RoCE = 7.80% (EBIT 785.0m / Capital Employed (Equity 5.86b + L.T.Debt 4.20b))
RoIC = 6.04% (NOPAT 656.5m / Invested Capital 10.86b)
WACC = 6.40% (E(8.46b)/V(13.54b) * Re(9.73%) + D(5.08b)/V(13.54b) * Rd(1.02%) * (1-Tc(0.16)))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.61%
[DCF] Terminal Value 85.38% ; FCFF base≈529.6m ; Y1≈587.9m ; Y5≈767.2m
[DCF] Fair Price = 130.2 (EV 19.36b - Net Debt 4.51b = Equity 14.85b / Shares 114.0m; r=6.40% [WACC]; 5y FCF grow 12.71% → 2.90% )
EPS Correlation: -39.81 | EPS CAGR: -23.62% | SUE: 0.21 | # QB: 0
Revenue Correlation: -79.37 | Revenue CAGR: -8.11% | SUE: -0.79 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.63 | Chg7d=-0.001 | Chg30d=-0.024 | Revisions Net=-2 | Analysts=14
EPS current Year (2026-12-31): EPS=5.82 | Chg7d=+0.000 | Chg30d=-0.156 | Revisions Net=-13 | Growth EPS=+7.3% | Growth Revenue=+0.8%
EPS next Year (2027-12-31): EPS=6.73 | Chg7d=+0.000 | Chg30d=-0.204 | Revisions Net=-8 | Growth EPS=+15.7% | Growth Revenue=+3.2%
[Analyst] Revisions Ratio: -0.25 (3 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.2% (Discount Rate 9.7% - Earnings Yield 5.5%)
[Growth] Growth Spread = -4.6% (Analyst -0.4% - Implied 4.2%)
P/E Forward = 12.5628
P/S = 0.9666
P/B = 1.4403
P/EG = 3.5907
Revenue TTM = 8.75b USD
EBIT TTM = 785.0m USD
EBITDA TTM = 1.30b USD
Long Term Debt = 4.20b USD (from longTermDebt, last quarter)
Short Term Debt = 642.0m USD (from shortTermDebt, last quarter)
Debt = 5.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.51b USD (from netDebt column, last quarter)
Enterprise Value = 12.97b USD (8.46b + Debt 5.08b - CCE 566.0m)
Interest Coverage Ratio = 3.62 (Ebit TTM 785.0m / Interest Expense TTM 217.0m)
EV/FCF = 30.59x (Enterprise Value 12.97b / FCF TTM 424.0m)
FCF Yield = 3.27% (FCF TTM 424.0m / Enterprise Value 12.97b)
FCF Margin = 4.84% (FCF TTM 424.0m / Revenue TTM 8.75b)
Net Margin = 5.42% (Net Income TTM 474.0m / Revenue TTM 8.75b)
Gross Margin = 21.07% ((Revenue TTM 8.75b - Cost of Revenue TTM 6.91b) / Revenue TTM)
Gross Margin QoQ = 17.13% (prev 19.66%)
Tobins Q-Ratio = 0.87 (Enterprise Value 12.97b / Total Assets 14.86b)
Interest Expense / Debt = 1.02% (Interest Expense 52.0m / Debt 5.08b)
Taxrate = 16.37% (93.0m / 568.0m)
NOPAT = 656.5m (EBIT 785.0m * (1 - 16.37%))
Current Ratio = 1.37 (Total Current Assets 3.65b / Total Current Liabilities 2.65b)
Debt / Equity = 0.85 (Debt 5.08b / totalStockholderEquity, last quarter 5.96b)
Debt / EBITDA = 3.48 (Net Debt 4.51b / EBITDA 1.30b)
Debt / FCF = 10.64 (Net Debt 4.51b / FCF TTM 424.0m)
Total Stockholder Equity = 5.86b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.15% (Net Income 474.0m / Total Assets 14.86b)
RoE = 8.09% (Net Income TTM 474.0m / Total Stockholder Equity 5.86b)
RoCE = 7.80% (EBIT 785.0m / Capital Employed (Equity 5.86b + L.T.Debt 4.20b))
RoIC = 6.04% (NOPAT 656.5m / Invested Capital 10.86b)
WACC = 6.40% (E(8.46b)/V(13.54b) * Re(9.73%) + D(5.08b)/V(13.54b) * Rd(1.02%) * (1-Tc(0.16)))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.61%
[DCF] Terminal Value 85.38% ; FCFF base≈529.6m ; Y1≈587.9m ; Y5≈767.2m
[DCF] Fair Price = 130.2 (EV 19.36b - Net Debt 4.51b = Equity 14.85b / Shares 114.0m; r=6.40% [WACC]; 5y FCF grow 12.71% → 2.90% )
EPS Correlation: -39.81 | EPS CAGR: -23.62% | SUE: 0.21 | # QB: 0
Revenue Correlation: -79.37 | Revenue CAGR: -8.11% | SUE: -0.79 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.63 | Chg7d=-0.001 | Chg30d=-0.024 | Revisions Net=-2 | Analysts=14
EPS current Year (2026-12-31): EPS=5.82 | Chg7d=+0.000 | Chg30d=-0.156 | Revisions Net=-13 | Growth EPS=+7.3% | Growth Revenue=+0.8%
EPS next Year (2027-12-31): EPS=6.73 | Chg7d=+0.000 | Chg30d=-0.204 | Revisions Net=-8 | Growth EPS=+15.7% | Growth Revenue=+3.2%
[Analyst] Revisions Ratio: -0.25 (3 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.2% (Discount Rate 9.7% - Earnings Yield 5.5%)
[Growth] Growth Spread = -4.6% (Analyst -0.4% - Implied 4.2%)